PhRMA: regulations, IP, reimbursement key for US growth
This article was originally published in SRA
Executive Summary
A strong, science-based regulatory system, coverage and payment policies that value innovative medicines, and robust intellectual property (IP) rights and enforcement in the US and abroad are among the 10 policy areas senior-level biopharmaceutical executives said are central to improving the business climate for the industry, according to a new report from Battelle1, which was commissioned by the Pharmaceutical Research and Manufacturers of America.